Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2- advanced breast cancer

CONCLUSIONS: From the perspective of Chinese payers, dalpiciclib plus NSAI appears to be a cost-effective strategy compared with abemaciclib plus NSAI for the first-line treatment of patients with HR+/HER2- ABC in China.PMID:38470447 | DOI:10.1080/14737167.2024.2330542
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Authors: Source Type: research